Agenus Stock Price, News & Analysis

Agenus Inc. (NASDAQ: AGEN) announced the appointment of Andy Hurley as Chief Commercial Officer, aimed at advancing the company's transition to a commercial stage. Garo Armen, the Chairman and CEO, emphasized Hurley's expertise in commercializing biopharmaceuticals as essential for Agenus' portfolio and potential product launches. Hurley expressed enthusiasm for leading the launch of balstilimab and other candidates within the pipeline. With over 30 years of experience, he previously served in senior roles at various biopharmaceutical companies, strengthening Agenus' leadership team.

Agenus Inc. (NASDAQ: AGEN) announced its inaugural Agenus Insights webinar titled “Optimally Targeting TIGIT” on February 11, 2021, at 1:00 p.m. ET. The event will feature a 15-minute presentation followed by a Q&A session led by Dr. Steven O’Day and Dr. Dhan Chand. The focus will be on the clinical validation of TIGIT as a cancer target and Agenus' innovative design. Registration is available online, and a replay will be accessible post-event on the company’s website.

Agenus Inc. (NASDAQ: AGEN) reported promising results from its Phase 1/2 trial of AGEN1181, a next-generation anti-CTLA-4 antibody. The trial confirmed six objective clinical responses in patients with colon, ovarian, and endometrial cancers, showcasing AGEN1181's efficacy, particularly in difficult-to-treat tumors. No significant toxicities were observed, marking a notable improvement over existing therapies like ipilimumab. Phase 2 trials in additional cancer indications are set to begin soon, highlighting the company's commitment to advancing cancer immunotherapy.

Agenus Inc. (NASDAQ: AGEN) reported positive preliminary results from its Phase 1 trial of iNKT cell therapy aimed at patients with moderate to severe COVID-19 symptoms. Conducted by AgenTus Therapeutics, the trial showcased that 3 out of 4 intubated patients were discharged after treatment, and 2 patients were extubated within 24 hours of dosing. The company is currently in the dose escalation phase, with plans to initiate a Phase 2 trial by mid-2021, and data readouts expected by Q4 2021. Early results indicate good tolerance and potential benefits of the therapy for severely ill patients.

Agenus Inc. (NASDAQ: AGEN) has announced a clinical collaboration with Nelum Corp. to evaluate the combination of zalifrelimab, its anti-CTLA-4 antibody, and Nelum's NLM-001 with chemotherapy for first-line advanced pancreatic cancer. The trial aims to assess the safety and efficacy of this combination. Under the agreement, Agenus will supply zalifrelimab, while Nelum will sponsor and conduct the trial, expected to begin enrolling in the first half of 2021. This collaboration is seen as a strategic move to enhance the therapeutic potential of Agenus' pipeline.

Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, and Dr. Steven O’Day, CMO, will participate in the B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021. The conference will feature a fireside chat with Dr. Buell on January 21 from 10:30 am to 11:00 am, accessible via a live webcast. Additionally, both doctors will engage in a panel discussion on novel immunotherapies. Recorded replays will be available on Agenus' Events & Presentations page post-conference.

Agenus Inc. (NASDAQ: AGEN) announced an updated timeline for the Biologics License Application (BLA) filing of balstilimab, necessitated by FDA feedback for a 12-month follow-up on all trial patients and a 6-month follow-up on responders. Two late responses in the clinical trial prompted this strategy adjustment, with the BLA filing now expected in the first half of 2021. The company is also clarifying PD-L1 diagnostic requirements with the FDA. This follow-up will provide data on patients achieving durable disease stabilization through long-term therapy.

Agenus Inc. (NASDAQ: AGEN) has expanded its Phase 2 trial for AGEN1181 in colorectal cancer following a promising clinical response. A significant tumor reduction of 27% was observed in a patient, alongside disease stabilization in 19 out of 41 treated patients. The trial also reported four clinical responses and the potential to treat tumors traditionally unresponsive to immune therapies. The company aims to broaden the patient population benefiting from cancer immunotherapies through innovative combination approaches.

Agenus Inc. (NASDAQ: AGEN) announced Dr. Jennifer Buell, President and COO, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, from 10:55 AM to 11:15 AM EST. Dr. Buell is set to provide updates on clinical programs, specifically AGEN1181, and the company's overall progress. Interested individuals can register for the webinar in advance. A replay will be available post-event on the Agenus website's Events & Presentations page.